Xeris Biopharma (XERS) Short Interest Ratio & Short Volume → Elon Musk Secret Crypto Plot Exposed (From Crypto 101 Media) (Ad) Free XERS Stock Alerts $1.85 -0.03 (-1.60%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Xeris Biopharma Short Interest DataCurrent Short Volume8,940,000 sharesPrevious Short Volume8,980,000 sharesChange Vs. Previous Month-0.45%Dollar Volume Sold Short$16.54 millionShort Interest Ratio / Days to Cover4.8Last Record DateApril 15, 2024Outstanding Shares148,250,000 sharesPercentage of Shares Shorted6.03%Today's Trading Volume1,025,420 sharesAverage Trading Volume2,023,381 sharesToday's Volume Vs. Average51% Short Selling Xeris Biopharma ? Sign up to receive the latest short interest report for Xeris Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatXERS Short Interest Over TimeXERS Days to Cover Over TimeXERS Percentage of Float Shorted Over Time Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. Xeris Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20248,940,000 shares $16.54 million -0.5%N/A4.8 $1.85 3/31/20248,980,000 shares $19.85 million -2.8%N/A4 $2.21 3/15/20249,240,000 shares $20.61 million -4.2%N/A4 $2.23 2/29/20249,640,000 shares $29.64 million +2.3%N/A4.2 $3.08 2/15/20249,420,000 shares $30.24 million +0.2%N/A4.6 $3.21 1/31/20249,400,000 shares $23.12 million -9.7%N/A4.7 $2.46 Get the Latest News and Ratings for XERS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/15/202410,410,000 shares $28.84 million +8.3%N/A5.5 $2.77 12/31/20239,610,000 shares $22.58 million +18.4%N/A6.6 $2.35 12/15/20238,120,000 shares $16.40 million -1.2%N/A6.2 $2.02 11/30/20238,220,000 shares $15.29 million -8.2%N/A7 $1.86 11/15/20238,950,000 shares $13.16 million +14.9%N/A8.1 $1.47 10/31/20237,790,000 shares $14.26 million +2.4%N/A8.4 $1.83 10/15/20237,610,000 shares $12.02 million -4.0%N/A8 $1.58 9/30/20237,930,000 shares $14.75 million +0.6%N/A8.4 $1.86 9/15/20237,880,000 shares $15.76 million +6.2%N/A7.5 $2.00 8/31/20237,420,000 shares $16.84 million -12.9%N/A6.9 $2.27 8/15/20238,520,000 shares $19.00 million +2.7%N/A7.8 $2.23 7/31/20238,300,000 shares $21.66 million -2.6%N/A7.1 $2.61 7/15/20238,520,000 shares $21.64 million +0.4%N/A7.2 $2.54 6/30/20238,490,000 shares $22.24 million -5.0%N/A6.5 $2.62 6/15/20238,940,000 shares $24.23 million +13.6%N/A6.7 $2.71 5/31/20237,870,000 shares $20.15 million -5.5%N/A6.2 $2.56 5/15/20238,330,000 shares $23.66 million -1.9%N/A6.3 $2.84 4/30/20238,490,000 shares $19.19 million +6.3%N/A6.9 $2.26 4/15/20237,990,000 shares $17.34 million +2.0%N/A7 $2.17 3/31/20237,830,000 shares $12.76 million -5.4%N/A6.7 $1.63 3/15/20238,280,000 shares $10.76 million +20.9%N/A7.6 $1.30 2/28/20236,850,000 shares $9.45 million +13.4%N/A6.9 $1.38 2/15/20236,040,000 shares $7.61 million -6.9%N/A6.8 $1.26 1/31/20236,490,000 shares $8.05 million +9.1%N/A7.7 $1.24 1/15/20235,950,000 shares $7.62 million +1.9%N/A6.8 $1.28 12/30/20225,840,000 shares $7.77 million +2.5%N/A6.5 $1.33 12/15/20225,700,000 shares $7.64 million -0.7%N/A7.3 $1.34 11/30/20225,740,000 shares $8.61 million -9.5%N/A7 $1.50 11/15/20226,340,000 shares $8.81 million +0.8%N/A7.7 $1.39 10/31/20226,290,000 shares $10.06 million +0.8%N/A7.6 $1.60 10/15/20226,240,000 shares $7.61 million -5.5%N/A7.2 $1.22 9/30/20226,600,000 shares $10.30 million -21.6%N/A8 $1.56 9/15/20228,420,000 shares $15.07 million -8.1%N/A8 $1.79 8/31/20229,160,000 shares $15.30 million -4.8%N/A8.3 $1.67Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. XERS Short Interest - Frequently Asked Questions What is Xeris Biopharma's current short interest? Short interest is the volume of Xeris Biopharma shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 8,940,000 shares of XERS short. Learn More on Xeris Biopharma's current short interest. What is a good short interest ratio for Xeris Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XERS shares currently have a short interest ratio of 5.0. Learn More on Xeris Biopharma's short interest ratio. Is Xeris Biopharma's short interest increasing or decreasing? Xeris Biopharma saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 8,940,000 shares, a drop of 0.4% from the previous total of 8,980,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Xeris Biopharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Xeris Biopharma: Pyxis Oncology, Inc. (4.78%), Ventyx Biosciences, Inc. (17.54%), Akebia Therapeutics, Inc. (6.54%), Verastem, Inc. (3.94%), RAPT Therapeutics, Inc. (9.14%), Nektar Therapeutics (1.75%), Werewolf Therapeutics, Inc. (1.40%), Inozyme Pharma, Inc. (7.66%), Aquestive Therapeutics, Inc. (4.40%), AC Immune SA (0.89%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Xeris Biopharma stock? Short selling XERS is an investing strategy that aims to generate trading profit from Xeris Biopharma as its price is falling. XERS shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Xeris Biopharma? A short squeeze for Xeris Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of XERS, which in turn drives the price of the stock up even further. How often is Xeris Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XERS, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: CTMX Short Interest Data XBIT Short Interest Data ENTA Short Interest Data RAPT Short Interest Data NKTR Short Interest Data ELYM Short Interest Data INZY Short Interest Data XOMA Short Interest Data VSTM Short Interest Data DSGN Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:XERS) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetry348 million Americans lives to END as we know it?The Oxford ClubThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe Exchange